High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
about
Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-CHOP therapy and intrathecal administration: a case report and review of literatureMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsOutcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature reviewMantle cell lymphoma: observation to transplantationCurrent and emerging therapies in mantle cell lymphoma.Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaEvaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS groupDurable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphomaA multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from thPhase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesPhase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science studyIndian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphomaFlavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyTemsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvementPevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoLong-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupMature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.The war on cancer: a report from the front linesVcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
P2860
Q24299054-E83D9D4E-5838-4D54-939C-B28C5468A1F2Q24681992-06A34670-D3D6-4AD6-9101-8D20B45B5BC1Q26772907-C30BCD5E-3BA0-49D3-95F7-770A3B15BEB1Q26859365-13DF5483-E747-445F-8AD4-B762787282ADQ28075606-D0F2347D-0ABF-4E5C-8FE3-5CB1B2FF4A0AQ28087748-3101F3E8-045F-47DE-B2C0-2B08BF59D2C1Q28256317-58FB426F-2493-4D0E-AD57-63E8EAA5D691Q30456545-044DBA07-25CD-493E-8E69-64954582E110Q30649483-AB81F563-6A03-48EC-B093-C713EF6C8C9CQ33388563-0C3B5054-02BD-4C60-9CA3-0D8465272CA3Q33388648-1A06C971-E01F-476A-B55B-D1881B8C0007Q33394873-B469F2FC-00EB-4374-9CE2-937C58376715Q33398818-8A3792B9-9D26-41BD-8ECB-63ADDCC419D7Q33399582-A79B7B39-549D-47EB-AEC8-CB7B093A68BCQ33408270-2E878E87-C89F-47F6-97DD-5CF637C36F93Q33416695-266BBF19-9CDA-429D-8962-49F4470EA695Q33423873-38C741F1-552D-4BAA-AB7B-4FD945E83071Q33425087-AB5E1E53-5D4A-4EBF-A4D3-A3E6A819D0CDQ33427312-18B8DB03-3697-44B3-9B4F-D78383AE458BQ33572807-2D4A6253-82E7-40E3-A19F-013437DFA042Q33583302-F36523FC-7BC3-4F8C-AD99-DEDE2857298DQ33585255-20055A97-AD77-4F66-B09B-5239367321DEQ33586239-228F999F-195C-484F-88E8-F67D4CA502FFQ33599174-3805AF84-70B9-40C4-8DB9-6AEF4537B619Q33627721-3444BEE0-E0B9-4297-9C4D-1C0303202C52Q33800959-19D2E63A-4180-4931-AE8F-00FC2068B9A5Q33802505-51489FC7-0295-442A-A457-2C21A44026E4Q34095473-0EDEBA76-7711-43B5-9ADB-C5DADB36274FQ34129360-0359A582-CEF5-4C6C-9ABB-8E029BF5D75AQ34131844-8BB54632-8956-4604-B2B1-AC7775450B80Q34183167-D6D71233-BAB9-4EE3-A9DF-FD4A8019236FQ34505392-81EFFC80-2439-45C7-85F0-54D70F951D78Q34594224-E13D9425-DF53-4782-A6B5-5CA547EB21EBQ34603567-1CE13CB6-C1BC-43EB-9259-0AF026B31903Q34997715-AE2BAFA2-A2A1-4149-81B2-241055516923Q35103643-24E9D5BA-C7AD-4AD8-B67D-77EBC2092731Q35285011-CE2707F1-F414-41A4-B979-6AB09F9C18CBQ35610286-87A7E1DB-430E-49EF-9E91-4E638937B9CBQ35629679-7255D305-B07E-49BB-BFFF-80AC4EB659CAQ35835983-C5E79513-089C-47F8-8A63-0E156D76D041
P2860
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
High rate of durable remission ...... e methotrexate and cytarabine.
@ast
High rate of durable remission ...... e methotrexate and cytarabine.
@en
High rate of durable remission ...... e methotrexate and cytarabine.
@nl
type
label
High rate of durable remission ...... e methotrexate and cytarabine.
@ast
High rate of durable remission ...... e methotrexate and cytarabine.
@en
High rate of durable remission ...... e methotrexate and cytarabine.
@nl
prefLabel
High rate of durable remission ...... e methotrexate and cytarabine.
@ast
High rate of durable remission ...... e methotrexate and cytarabine.
@en
High rate of durable remission ...... e methotrexate and cytarabine.
@nl
P2093
P356
P1476
High rate of durable remission ...... e methotrexate and cytarabine.
@en
P2093
Anas Younes
Andreas H Sarris
Barbara Pro
Barry I Samuels
Felipe Samaniego
Fernando F Cabanillas
Frederick B Hagemeister
Harish Gagneja
Jorge E Romaguera
P304
P356
10.1200/JCO.2005.01.1825
P407
P50
P577
2005-09-06T00:00:00Z